Butterfly Network, Inc. (BFLY) Q3 2024 Earnings Call Transcript Summary
Butterfly Network, Inc. (BFLY) Q3 2024 Earnings Call Transcript Summary
Adjusted The following is a summary of the Butterfly Network, Inc. (BFLY) Q3 2024 Earnings Call Transcript:
以下是Butterfly Network, Inc. (BFLY) Q3 2024業績會實錄摘要:
Financial Performance:
金融業績：
Butterfly Network reported Q3 2024 revenue of $20.6 million, marking a 33% year-over-year increase.
Gross profit increased to $12.2 million, up 30% from the previous year, although gross margin percentage slightly decreased to 59.5%.
Adjusted EBITDA loss improved by 33% to $8.4 million from a loss of $12.5 million year-over-year.
They anticipate Q4 2024 revenue to be in the range of $20 to $22 million with an expected adjusted EBITDA loss of $10 to $12 million.
Butterfly Network報告了2024年第三季度營業收入爲2060萬美元，同比增長33%。
毛利潤增加至1220萬美元，比去年同期增長30%，儘管毛利率略微下降至59.5%。
調整後的EBITDA虧損從去年1250萬美元的虧損減少33%至840萬美元。
他們預計2024年第四季度營業收入將在20到2200萬美元區間內，預計調整後的EBITDA虧損爲10到1200萬美元。
Business Progress:
業務進展：
Introduced four strategic pillars during an Investor Day including accelerating core business growth, advancing R&D, expanding into new markets, and improving operational efficiency.
Launched iQ3 domestically and internationally, and implemented the ScanLab AI training app.
Established partnerships and expanded into new markets including Indonesia, Netherlands, Belgium, and more.
Announced the formation of Octiv, a subsidiary focused on licensing and commercializing ultrasound technology.
在投資者日引入了四個戰略支柱，包括加速核心業務增長，推動研發，進軍新市場，以及提高運營效率。
在國內和國際推出了iQ3，並實施了ScanLab 人工智能訓練應用程序。
建立了合作伙伴關係，並擴展到印度尼西亞、荷蘭、比利時等新市場。
宣佈成立Octiv，這是一家側重於許可和商業化超聲技術的子公司。
Opportunities:
機會：
Expansion into home care services with a pilot for virtual chronic care management services starting in Q4 2024, targeting the Medicare advantage provider segment.
Launched iQ3 internationally, broadening the product's global reach and aiming for revenue growth in 2025 from higher average selling prices and additional probes in distribution.
Developing proprietary Butterfly iQ Station and forthcoming P5 chip technologies for entering ultrasound cart markets.
擴展到家庭護理服務，從2024年第四季度開始試點虛擬慢性護理管理服務，目標是Medicare優勢提供商領域。
在國際上推出了iQ3，擴大了產品的全球影響力，並旨在通過更高的平均售價和分佈渠道中的其他探針實現2025年營業收入增長。
開發專有的Butterfly iQ Station和即將推出的P5芯片技術，以進入超聲波設備市場。
Risks:
風險：
Consumer acceptance and market penetration for new product launches like iQ3 and upcoming technologies could affect future revenue projections.
Dependency on strategic partnerships and international market expansions that involve complex regulatory and market dynamics.
消費者對新產品發佈的接受程度和市場滲透，如iQ3和即將推出的技術，可能會影響未來的營業收入預測。
依賴戰略合作伙伴關係和涉及複雜監管和市場動態的國際市場擴張。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由AI生成。文章內容的準確性無法完全保證。有關更全面的詳細信息，請參閱IR網站。本文只是爲投資者提供參考，沒有任何指導或推薦建議。
